Our Services
Medical Information
Helpful Resources
Published on: 3/12/2026
Low dose ketamine IV infusions in a monitored clinical setting can offer rapid relief for treatment resistant depression, often using about 0.5 mg/kg over 40 minutes in a series of six treatments, with some patients moving to maintenance sessions.
Candidacy, safety, and access vary, and key details about benefits, side effects, monitoring needs, costs, and how this differs from esketamine may shape your next steps; there are several factors to consider, so see below for the complete information.
If you've tried antidepressants, therapy, lifestyle changes—and you're still depressed—you're not alone. Up to one‑third of people with major depressive disorder (MDD) do not respond adequately to standard treatments. This is often called treatment‑resistant depression (TRD).
In recent years, a new option has gained attention in psychiatric medicine: the low dose ketamine infusions for depression protocol. Backed by growing clinical research from major medical centers, ketamine offers something many traditional antidepressants do not—rapid relief for some patients.
Here's what you need to know.
Ketamine has been used safely for decades as an anesthetic in surgery and emergency medicine. At much lower doses, however, it has powerful antidepressant effects.
Unlike standard antidepressants that affect serotonin or norepinephrine, ketamine works primarily on the glutamate system, specifically the NMDA receptor. This difference matters.
Research suggests ketamine may:
Traditional antidepressants can take 4–8 weeks to work. Ketamine may begin working within hours to days for certain individuals.
The low dose ketamine infusions for depression protocol is a medically supervised treatment delivered through an IV in a clinical setting.
After the initial series, some patients move to:
This protocol is based on landmark clinical trials published in peer‑reviewed psychiatric journals and refined through years of academic medical practice.
Low dose ketamine infusions are generally considered for:
It is not usually a first-line treatment. Most doctors recommend trying standard therapies first unless symptoms are severe or urgent.
If you're not sure whether what you're experiencing aligns with clinical depression, taking a free Depression symptom checker can help you identify patterns in your symptoms and prepare for a more informed conversation with your doctor.
Clinical studies show:
However, response varies:
Ketamine is not a cure—but for some, it can be a powerful tool that creates a window for healing.
During a low dose infusion, patients often describe:
These effects typically:
Most patients are able to go home the same day but cannot drive and must arrange transportation.
When delivered in a controlled medical setting, low dose ketamine infusions are generally considered safe.
Common short-term side effects may include:
These usually resolve shortly after treatment.
Ketamine has abuse potential when used recreationally. However, addiction risk appears low when used in structured, clinical protocols under supervision.
You may have heard of esketamine nasal spray, an FDA-approved medication derived from ketamine.
Key differences:
IV ketamine infusions are:
Both approaches can be effective. A psychiatrist can help determine which option is appropriate.
Many patients experience significant improvement after 6 infusions. After that, options may include:
Ketamine often works best when combined with:
The rapid symptom relief may allow patients to engage more effectively in therapy.
You may want to discuss the low dose ketamine infusions for depression protocol with a psychiatrist if:
However, ketamine is not appropriate for everyone. A thorough medical and psychiatric evaluation is essential.
Because IV ketamine for depression is often used off-label:
Be cautious of clinics that:
Ketamine is a medical treatment—not a miracle cure.
Major academic institutions have published findings showing:
However:
Depression is complex. Ketamine is one tool—not the entire toolbox.
It's important not to overhype ketamine—but also not to dismiss it.
For people who have felt stuck for years, low dose ketamine infusions for depression protocol has provided meaningful relief. For others, it may offer temporary improvement while building a longer-term treatment plan.
The key is proper medical guidance.
If your depression includes:
You should speak to a doctor immediately. If you believe you are in danger, seek emergency care. Depression can be life-threatening, and urgent help is available.
If you are still depressed despite treatment, you are not broken—and you are not out of options.
The low dose ketamine infusions for depression protocol represents one of the most important developments in modern psychiatric care. It offers:
Before making any decisions:
Most importantly, speak to a doctor about any symptoms that feel severe, life-threatening, or overwhelming.
Depression is serious—but it is treatable. And new options continue to emerge.
(References)
* Saeed B, Ma S, Rofail D, Almaghrabi H, Adewole A. Efficacy and safety of ketamine and esketamine in the treatment of major depressive disorder: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020 Jul 14;19:35. doi: 10.1186/s40345-020-00206-8. PMID: 32670273; PMCID: PMC7360980.
* Matuskey D, Corlett PR, Niciu MJ, Zarkowsky P, D'Souza DC, Krystal JH. Intravenous Ketamine for Depression: A Practical Guide. J Clin Psychiatry. 2018;79(4):17nr11858. doi: 10.4088/JCP.17nr11858. PMID: 29707920; PMCID: PMC6118042.
* Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Charney DS, Mathew SJ. Rapid and Sustained Antidepressant Effects of Intravenous Ketamine in Patients With Treatment-Resistant Major Depressive Disorder: A Systematic Review and Meta-analysis. Biol Psychiatry. 2016 Sep 1;80(5):e33-40. doi: 10.1016/j.biopsych.2016.05.003. Epub 2016 May 13. PMID: 27278775; PMCID: PMC5003612.
* Saleh A, Krivoy A, Agur Z, Nini A, Harel A, Shbiro F. Efficacy and Safety of Repeated Ketamine Infusions for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol. 2020 May 29;23(5):309-325. doi: 10.1093/ijnp/pyaa014. PMID: 32240212.
* Sanacora G, Frye MA, McDonald W, Goff D, Kelsey R, Malhi GS, Nemeroff CB, Ostroff RB, Patkar AA, Schatzberg AF, Seedat S, Shappell P, Wilkinson ST. A Consensus Statement on the Use of Ketamine in Patients With Treatment-Resistant Depression. JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080. Epub 2017 Feb 15. PMID: 28203527.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.